Literature DB >> 35747063

Loperamide-induced ventricular tachycardia storm.

Mohamed Daoub1, Philippa Cawley1, Jonathan Sahu2.   

Abstract

Loperamide is an over-the-counter, peripherally-acting, μ-opioid receptor agonist commonly used in the treatment of diarrhoea. It has increasingly been recognised as a potential drug of misuse, having previously been thought to have low potential for abuse owing to its low bioavailability and poor penetration of the central nervous system. High doses can result in life-threatening cardiac-toxicity. We present a case of a young woman who had been self-treating her depression with high doses of loperamide for one year, who then presented to hospital with syncope secondary to ventricular tachycardia (VT). While in the emergency department (ED) the patient had monomorphic pulseless VT requiring electrical cardioversion multiple times. Transfer to a tertiary cardiac centre was immediately arranged after she was stabilised and intubated. This complicated the diagnostic process as a thorough history could not be obtained on arrival to the tertiary centre, which meant the loperamide misuse only came to light multiple days into admission, after the patient was extubated. The final diagnosis of loperamide-induced secondary long-QT syndrome was made and the patient made a full recovery.
Copyright © 2021 Medinews (Cardiology) Limited.

Entities:  

Keywords:  loperamide; ventricular tachycardia

Year:  2021        PMID: 35747063      PMCID: PMC9063705          DOI: 10.5837/bjc.2021.046

Source DB:  PubMed          Journal:  Br J Cardiol        ISSN: 0969-6113


  9 in total

1.  Loperamide induced cardiac arrhythmia successfully supported with veno-arterial ECMO (VA-ECMO), molecular adsorbent recirculating system (MARS) and continuous renal replacement therapy (CRRT).

Authors:  Brandon Masi Parker; Tejaus Rao; Ann Matta; Megan Quitanna; H Neal Reynolds; Deborah M Stein; Daniel Haase
Journal:  Clin Toxicol (Phila)       Date:  2019-02-26       Impact factor: 4.467

2.  Loperamide toxicokinetics: serum concentrations in the overdose setting.

Authors:  William Eggleston; Nicholas Nacca; Jeanna M Marraffa
Journal:  Clin Toxicol (Phila)       Date:  2015-03-30       Impact factor: 4.467

Review 3.  Loperamide cardiotoxicity: "A Brief Review".

Authors:  Tamer Akel; Soad Bekheit
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-11-10       Impact factor: 1.468

4.  Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.

Authors:  Jiesheng Kang; David R Compton; Roy J Vaz; David Rampe
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-08-16       Impact factor: 3.000

5.  Unexpected Serious Cardiac Arrhythmias in the Setting of Loperamide Abuse.

Authors:  Somwail Rasla; Parag Parikh; Amy St Amand; Marina K Garas; Amr El Meligy; Taro Minami; Nishant R Shah
Journal:  R I Med J (2013)       Date:  2017-04-03

6.  Loperamide Trends in Abuse and Misuse Over 13 Years: 2002-2015.

Authors:  Daniel R Lasoff; Cynthia H Koh; Bryan Corbett; Alicia B Minns; F Lee Cantrell
Journal:  Pharmacotherapy       Date:  2017-01-24       Impact factor: 4.705

7.  Potent Inhibition of hERG Channels by the Over-the-Counter Antidiarrheal Agent Loperamide.

Authors:  Michael G Klein; Mark C P Haigney; Philip S Mehler; Naheed Fatima; Thomas P Flagg; Mori J Krantz
Journal:  JACC Clin Electrophysiol       Date:  2016-09-14

8.  "I just wanted to tell you that loperamide WILL WORK": a web-based study of extra-medical use of loperamide.

Authors:  Raminta Daniulaityte; Robert Carlson; Russel Falck; Delroy Cameron; Sujan Perera; Lu Chen; Amit Sheth
Journal:  Drug Alcohol Depend       Date:  2012-11-30       Impact factor: 4.492

9.  Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride.

Authors:  J M Killinger; H S Weintraub; B L Fuller
Journal:  J Clin Pharmacol       Date:  1979-04       Impact factor: 3.126

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.